Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 307Recurrence 64Neoplasms 32Neoplasms, Plasma Cell 17Lymphoma, Non-Hodgkin 14Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Vomiting 11Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Nausea 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Ovarian Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Hematologic Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Paraproteinemias 5Lung Neoplasms 5Leukemia 5Small Cell Lung Carcinoma 4Renal Insufficiency 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Plasmacytoma 4Lymphoma, Follicular 4Hematologic Diseases 4Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3

Interventions

Bortezomib 3ricolinostat 1pomalidomide 1ficlatuzumab 1Zoledronic Acid 1Vorinostat 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Dexamethasone 1Denosumab 1CLR1404 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Blood Protein Disorders × Dexamethasone × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡